Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Blogs » ED Push » Study Argues Against Prehospital Antiplatelet Therapy in STEMI

    ED Push
    ED Push RSS FeedRSS

    edpush-webheader-rm

    Free Monthly News from the Award Winning Publisher of:

    • Emergency Medicine Reports
    • Trauma Reports
    • Critical Care Alert
    • ED Management
    • ED Legal Letter
    • Pediatric Emergency Medicine Reports
    • EM Reports' Study Guide 2018
    • STROKE: The Cutting Edge: 2017
    • Pediatric Trauma 2018
    • STEMI Watch 2018
     

     

    Study Argues Against Prehospital Antiplatelet Therapy in STEMI

    September 15, 2017
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share
    By Brenda Mooney

    A new study finds that providing antiplatelet therapy to patients with ST-elevation myocardial infarction (STEMI) provides no significant advantages over in-hospital treatment.

    Although prehospital antiplatelet therapy is recommended for STEMI patients in many clinical guidelines in both North America and Europe, the study authors hope their findings will discourage the current practice.

    The study, presented at the European Society of Cardiology (ESC) conference in Barcelona, Spain, suggests that it might be more prudent to wait and administer the therapy once the patent arrives at the hospital emergency department (ED).

    “Prehospital administration is common practice — despite the lack of definite evidence for its benefit,” pointed out investigator Elmir Omerovic, PhD, from Sahlgrenska University Hospital in Gothenburg, Sweden. “But our study — which is the largest cohort study conducted so far — adds to some previous evidence suggesting there is potential for harm. In fact, inadvertent prehospital administration of these drugs to patients with contraindications to antithrombotic therapy is common. Therefore, considering all current evidence, we think prehospital administration should be discouraged.”

    To come to that conclusion, the research team conducted a retrospective study employing data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) to identify 44,804 STEMI patients undergoing percutaneous coronary intervention (PCI) — a revascularization procedure — between 2005 and 2016.

    Although most of the patients were pretreated with antiplatelet therapy, 6,964 were not. That enabled the researchers to compare pretreated patients to those not pretreated; and they found no significant benefits of pretreatment in terms of 30-day mortality (odds ratio 0.91) or other endpoints, including measures of arterial blockage, cardiogenic shock, neurological complications, or bleeding complications.

    Prehospital antiplatelet treatment is recommended by the ESC, the American College of Cardiology, and the American Heart Association, according to the study. Results based on the ATLANTIC trial — presented at the ESC Congress within the last few years — first raised questions about whether pretreatment was advantageous, but involved relatively short delays for patients receiving in-hospital treatment, Omerovic pointed out.

    “Our new data addresses some of the concerns with ATLANTIC and offers stronger evidence that pretreatment is not necessary,” he said. “We hope the accumulated evidence will be convincing enough to discourage this practice and trigger a change in recommendations.”

     

    newsletter-sponsors-relias_sr

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    ED Push

    View PDF
    ED Push - September 2017 Second Issue
    September 15, 2017

    Table Of Contents

    Study Argues Against Prehospital Antiplatelet Therapy in STEMI

    Racial, Ethnic Differences Found in Pediatric Antibiotic Prescribing at EDs

    ED Visits, Healthcare Costs Increase When Spouses of Disabled Are Suffering

    “Avoidable” ED Visits Tend to Fall Into Mental Health, Dental Categories

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing